Know Cancer

or
forgot password

Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised Study


N/A
18 Years
80 Years
Open (Enrolling)
Both
Lymphoma

Thank you

Trial Information

Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised Study


Inclusion Criteria:



Age over 18, with Hodgkin’s lymphoma or with large B and P cell non-Hodgkin’s lymphoma, or
after a first-line chemotherapy with at least a residual mass or after induction
chemotherapy or at progression.

Stem cell transplantation would be programmed. Patients were required to give their
written informed consent.

Exclusion Criteria:

Progressive cancer or diagnosed less than 5 years, except cancer in situ of the cervix and
basocell skin carcinoma, kidney insufficiency or diabetes. Patients would not be pregnant
or lactating

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

The impact of positron emission tomography (PET) using fluorine-18-floro-deoxyglucose (FDG) in the therapeutic prescription in patients with Hodgkin’s lymphoma or with large B and P cell non-Hodgkin’s lymphoma.

Principal Investigator

Gilles SALLES, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hospices Civils de Lyon

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

2000.232

NCT ID:

NCT00169598

Start Date:

February 2002

Completion Date:

Related Keywords:

  • Lymphoma
  • Lymphoma
  • positron emission tomography
  • stem cell transplantation
  • therapeutic impact
  • Lymphoma

Name

Location